论文部分内容阅读
含有铂类化合物的联合化疗能提高晚期卵巢癌患者的生存率,但多数患者仍不可避免地死于该病。因此,研制一种新的,没有交叉抗药性的药物显然很有必要。2＇,2＇-二氟脱氧胞苷(Gemcitabine)在离休肿瘤培养细胞和动物肿
Combination chemotherapy with platinum compounds can increase the survival rate of patients with advanced ovarian cancer, but most patients still inevitably die from the disease. Therefore, the development of a new drug without cross-resistance is clearly necessary. 2 ’, 2’-difluorodeoxycytidine (Gemcitabine) in retired tumor cells and animal swollen